Co-Authors
This is a "connection" page, showing publications co-authored by LAUREN AVERETT BYERS and JING WANG.
Connection Strength
1.797
-
Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014 Jul 31; 511(7511):543-50.
Score: 0.508
-
Teaching an old dog new tricks: drug repositioning in small cell lung cancer. Cancer Discov. 2013 Dec; 3(12):1333-5.
Score: 0.487
-
drexplorer: A tool to explore dose-response relationships and drug-drug interactions. Bioinformatics. 2015 May 15; 31(10):1692-4.
Score: 0.132
-
Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer. Clin Cancer Res. 2013 Nov 15; 19(22):6322-8.
Score: 0.120
-
An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res. 2013 Jan 01; 19(1):279-90.
Score: 0.113
-
Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov. 2012 Sep; 2(9):798-811.
Score: 0.112
-
Blasted cell line names. Cancer Inform. 2010 Oct 14; 9:251-5.
Score: 0.098
-
Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer. Clin Cancer Res. 2009 Nov 15; 15(22):6852-61.
Score: 0.092
-
Genes suppressed by DNA methylation in non-small cell lung cancer reveal the epigenetics of epithelial-mesenchymal transition. BMC Genomics. 2014 Dec 08; 15:1079.
Score: 0.033
-
Aberrant expression of proteins involved in signal transduction and DNA repair pathways in lung cancer and their association with clinical parameters. PLoS One. 2012; 7(2):e31087.
Score: 0.027
-
Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst. 2012 Feb 08; 104(3):228-39.
Score: 0.027
-
Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non-small-cell lung carcinoma who receive adjuvant chemotherapy. Cancer Res. 2011 Aug 15; 71(16):5512-21.
Score: 0.026
-
Proteomic profiling identifies pathways dysregulated in non-small cell lung cancer and an inverse association of AMPK and adhesion pathways with recurrence. J Thorac Oncol. 2010 Dec; 5(12):1894-904.
Score: 0.025